AG
SNNA

Artal Group’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Artal Group’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-99,000
Closed -$1.5M – 122
2018
Q2 		$1.5M Buy
+99,000
New +$1.68M 0.03% 96

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group's SNNA Position: Q3 2018 in Review

Artal Group sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2018, closing a stake of 99,000 shares — an estimated $1.5M sold.

Artal Group first reported a position in SNNA in Q2 2018 and held it in 1 quarter. The position peaked at $1.5M in Q2 2018. 54 funds tracked by Wall St. Rank hold SNNA as of Q3 2018.

  • Artal Group reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Artal Group sold 99,000 Sienna Biopharmaceuticals, Inc. shares in Q3 2018, an estimated $1.5M.
  • Artal Group first reported a position in Sienna Biopharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Artal Group's Sienna Biopharmaceuticals, Inc. position peaked at $1.5M in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2018.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.